Neuropeptide levels in discrete brain regions in the iminodipropionitrile-induced persistent dyskinesia rat model

Ameliorative effect of gastrodin on 3,3'-iminodipropionitrile-induced memory impairment in rats

3,3'-Iminodipropionitrile (IDPN), one of the nitrile derivatives inducing neurotoxicity, causes the dyskinetic syndrome and cognitive impairment. Gastrodin is widely used to treat neurological disorders and showed to improve cognitive functions. The present study aimed to determine whether treatment with gastrodin can attenuate IDPN-induced impairment of memory consolidation in the passive avoidance (PA) task, and to explore the possible neural mechanisms. Our results showed that intragastric administration of gastrodin (200mg/kg) reversed the IDPN-induced impairment of memory consolidation as indicated by the prolonged retention latency in the PA task. Furthermore, gastrodin reverted IDPN-induced reduction of serotonin (5-HT) and elevation of serotonin turnover ratio. Gastrodin treatment prevented the increase of serotonin transporter (SERT) and the decrease of serotonin 1A (5-HT1A) receptor expression in the hippocampus of IDPN-treated rats. These results suggest that long-term gastrodin treatment could represent a novel pharmacological strategy for IDPN-induced memory impairment, as well that its protective effect is mediated through normalization of the serotoninergic system.

Dual ameliorative effects of Ningdong granule on dopamine in rat models of Tourette's syndrome

Dopamine (DA) is a key neuromodulator in the brain that supports motor and cognitive functions. Here, we use apomorphine (Apo) and 3,3'-iminodipropionitrile (IDPN) to develop two rat models of Tourette's syndrome (TS), a common neuropsychiatric disorder characterized by stereotyped repetitive involuntary tics. The models enabled the assessment of unique ameliorative effects of Ningdong granule (NDG), a traditional Chinese medicine (TCM) preparation dedicated to the treatment of TS, on the striatal DA content of rats. By using high-performance liquid chromatography (HPLC), we found that long-term administration of NDG could, at least partially, restore the striatal dopamine alterations, either by increasing them after IDPN treatment or by decreasing them after Apo treatment. Taken together, our data indicated that NDG could ameliorate the abnormal striatal DA content dually, and the unique therapeutic property may be meaningful for the treatment of TS.

Gastrodin ameliorates memory deficits in 3,3'-iminodipropionitrile-induced rats: possible involvement of dopaminergic system

3,3'-Iminodipropionitrile (IDPN), one of the nitrile derivatives, can induce neurotoxicity, and therefore cause motor dysfunction and cognitive deficits. Gastrodin is a main bioactive constituent of a Chinese herbal medicine (Gastrodia elata Blume) widely used for treating various neurological disorders and showed greatly improved mental function. This study was designed to determine whether administration of gastrodin attenuates IDPN-induced working memory deficits in Y-maze task, and to explore the underlying mechanisms. Results showed that exposure to IDPN (150 mg/kg/day, v.o.) significantly impaired working memory and that long-term gastrodin (200 mg/kg/day, v.o.) could effectively rescue these IDPN-induced memory impairments as indicated by increased spontaneous alternation in the Y-maze test. Additionally, gastrodin treatment prevented IDPN-induced reductions of dopamine (DA) and its metabolites, as well as elevation of dopamine turnover ratio (DOPAC + HVA)/DA. Gastrodin treatment also prevented alterations in dopamine D2 receptor and dopamine transporter protein levels in the rat hippocampus. Our results suggest that long-term gastrodin treatment may have potential therapeutic values for IDPN-induced cognitive impairments, which was mediated, in part, by normalizing the dopaminergic system.

Histological insights in iminodipropionitrile-induced toxicity in rats

Iminodipropionitrile (IDPN) is a prototype nitrile compound that produces excitation, chorea and circling (ECC) syndrome in rodents. Previous studies have implicated vestibular hair cell degeneration in IDPN-induced behavioral abnormalities. Although the pathological changes in vestibular labyrinth of IDPN-treated rats are well documented, the effects of IDPN on other organ systems are not clearly understood. We therefore examined the histopathological alterations in inner ear, brain, liver and kidneys of rats exposed to IDPN. Adult male Wistar rats were divided into two groups of six animals each. Control rats received normal saline whereas the IDPN group was treated with IDPN (100mg/kg, i.p.) daily for 7 days. All the animals were carefully observed for any behavioral abnormality and the dyskinetic movements including the vertical and horizontal head weaving, circling and backward walking were quantified. The animals were sacrificed on day 9 and the samples of cochlea, brain, liver and kidney were collected for histopathology. The results showed a direct correlation between the severity of behavioral deficits and the cellular damage in crista ampullaris in IDPN-treated rats. Histopathology of liver was severely influenced by IDPN treatment, leading to vacuolization of cytoplasm, distorted sinusoids, infiltration of mononuclear cells and necrotic zones. However, the severity of hepatic damage in IDPN-treated rats was independent of the magnitude of vestibular hair cell degeneration as well as the severity of behavioral deficits. Administration of IDPN in the vestibulotoxic doses did not produce any histological changes in the brain cortex and kidneys of rats.

Behavioral pharmacology of orofacial movement disorders

Dysfunction in orofacial movement is evident in patients with schizophrenia, Parkinson's disease and Huntington's disease. In animal studies on orofacial dyskinesia, these neurological disorders have been considered as a starting point to examine the pathophysiology and mechanisms underlying the symptoms. There is circumstantial evidence that orofacial dyskinesia in humans might be the consequence of hyperfunctioning mesolimbic-pallidal circuitry, in which the mesolimbic region occupies a central role, in contrast to typical Parkinson-like symptoms which involve hypofunction in the nigrostriato-nigral circuity. Studies in animals suffer from technical difficulties concerning the assessment of orofacial behaviors. There are some experimental designs that provide detailed information on the amplitude and the frequency of the jaw movements. By using such methods, the involvement of neurotransmitter systems and functional neural connections within the basal ganglia has been studied in rat rhythmical jaw movements. Regarding neurotransmitter systems, dopaminergic, cholinergic, γ-aminobutyric acid (GABA)ergic and glutamaterigic systems have been shown to be involved in rat rhythmical jaw movements. The involved neural connections have also been investigated, focusing on the differential role between the dorsal and ventral part of the striatum, the shell and core of the nucleus accumbens and the output pathways from the striatum and the nucleus accumbens. Taking available clinical and experimental evidence, the orofacial dyskinesias are thought to arise when hierarchically lower order output stations of the mesolimbic region start to dysfunction as a consequence of the arrival of distorted information sent by the mesolimbic region. This review seeks to provide an overview of prior and recent findings across several orofacial movement disorders and interpret new insights in the context of the limitations of behavioral pharmacology and prior knowledge of the regulation of behavior by dopamine receptors and other related neuronal systems.

Neurovestibular toxicities of acrylonitrile and iminodipropionitrile in rats: a comparative evaluation of putative mechanisms and target sites

This investigation was aimed to study the effects of individual and concomitant exposures of the two nitrile compounds, the industrially important acrylonitrile (ACN; 5, 15, 45 mg/kg/day) and the positive control iminodipropionitrile (IDPN; 100 mg/kg/day) in rats. The six treatment groups were 1 (control), 2 (ACN 5), 3 (ACN 15), 4 (ACN 45), 5 (IDPN), and 6 (IDPN + ACN 15). Both the drugs were started on the same day and continued for 9 days (IDPN was given daily 30 min before ACN but stopped a day earlier). The animals were daily observed for neurobehavioral abnormalities including dyskinetic head movements, circling, tail hanging, air righting reflex, and contact inhibition of righting reflex. There was no dyskinetic behavioral abnormality in the animals treated with any of the three doses of ACN whereas all the rats in IDPN alone treated group developed clear symptoms of excitation, circling, and chorea syndrome (ECC syndrome) on day 9. Concomitant treatment of rats with ACN significantly attenuated the severity of IDPN-induced behavioral deficits. Administration of ACN significantly depleted glutathione (GSH) in striatum, hippocampus and cerebral cortex; IDPN significantly reduced the GSH only in striatum. The anterior striatum showed intense tyrosine hydroxylase (TH) expression in IDPN alone treated rat as compared to control and ACN alone treated rat. Cotreatment with ACN reduced the intensity of TH immunostaining in IDPN-treated rats. Administration of IDPN alone caused massive loss of vestibular sensory hair cells in the crista ampullaris whereas the sensory epithelium appeared intact in ACN alone treated groups. The animals receiving the combination of ACN and IDPN showed comparatively less degeneration of sensory hair cells than IDPN alone group. These findings suggest that ACN and IDPN produce different behavioral effects that are exerted through entirely different mechanisms; the nervous and vestibular systems appear to be the major target sites of these toxins, respectively.

Expression of neurotransmitter genes in motor regions of the dyskinetic rat after iminodipropionitrile

Rats treated with iminodipropionitrile develop a neurobehaviour syndrome with dyskinesia. Searching for the molecular correlates, we have examined the expression of selected genes involved in neurotransmission in motor regions using hybridization histochemistry. Frontal cortical and thalamic vasoactive intestinal peptide (VIP) expression, and striatal dynorphin, enkephalin (ENK) and substance P expression were increased. No change in cortical cholecystokinin (CCK), ENK, glutamic acid decarboxylase (GAD) and somatostatin (SRIF) expression, in striatal GAD, SRIF, nitric oxide synthase (NOS) and guanylate cyclase expression, and in thalamic CCK, GAD and thyrotropin-releasing hormone expression was found. NOS expression in the subthalamic nucleus as well as tyrosine hydroxylase, GAD and CCK expression in the substantia nigra were unchanged. These results confirm the involvement of striatal projection neurons in dyskinesia and suggest a novel role for VIP.

Proglumide, a cholecystokinin receptor antagonist, exacerbates beta, beta'-iminodipropionitrile-induced dyskinetic syndrome in rats

The present investigation was undertaken to study the effect of proglumide, a cholecystokinin (CCK) receptor antagonist, on iminodipropionitrile (IDPN)-induced excitation, chorea, and circling (ECC) syndrome in rats. The animals were exposed to IDPN in the dose of 100 mg/kg/day IP for 9 days. Proglumide (PG) was administered IP daily 1 h before IDPN in the doses of 250, 500, and 750 mg/kg body weight in three different groups of rats. The animals were observed daily for neurobehavioral abnormalities including dyskinetic head movements, circling, tail hanging, air righting reflex, locomotor activity, and contact inhibition of the righting reflex. After behavioral studies, blood and brain samples were collected for the analysis of malondialdehyde (MDA), conjugated dienes, vitamin E, and glutathione peroxidase (GSH-Px). The temporal bones were also collected for inner ear histopathology. Our results showed that proglumide significantly and dose-dependently exacerbated the incidence and the severity of IDPN-induced ECC syndrome during the treatment period as well as up to 3 weeks of postdosing. Administration of IDPN produced a significant increase in MDA and conjugated dienes and a decrease in vitamin E and GSH-Px, suggesting the role of oxygen-derived free radicals (ODFR) in IDPN-induced neurotoxicity. Concomitant treatment with proglumide potentiated IDPN-induced oxidative stress. The histopathology of the inner ear showed significantly high degeneration of sensory hair cells in the crista ampullaris of the rats treated with IDPN plus proglumide compared to IDPN-alone-treated animals. Further studies are warranted to determine the role of CCK in nitrile toxicity and drug-induced dyskinesia.

Effects of iminodipropionitrile on cerebral amino acid levels

Iminodipropionitrile (IDPN), a compound that causes dyskinetic symptoms in animals and has possible use as a model for human dyskinesia, was tested in mice and rats for its effect on cerebral amino acids. In mice, 2 h after IDPN administration, the level of total brain alanine was reduced; after 5 h the levels of aspartic acid and glutamic acid were also reduced, and the level of glutamine was increased. In rats, after chronic administration of IDPN, the level of glutamic acid in the total brain tissue was reduced. After acute administration of IDPN using microdialysis, extracellular GABA and extracellular glutamine levels in the striatum were elevated. This study shows that IDPN causes alterations in total and extracellular levels of neurotransmitter amino acids in the brain, which could have a role in IDPN-induced dyskinesia.